According to analysis by cancer type, no significant association was noted between the CCND1 G870A polymorphism and an increased risk of CRC in patients with sCRC (AA + AG vs GG: OR = 1.24, 95% CI = 0.96–1.60) and HNPCC (AA + AG vs GG: OR = 0.93, 95% CI = 0.64–1.36), but a significantly increased CRC risk was found in sCRC patients with genotype AG (AG vs GG: OR = 1.30, 95% CI = 1.11–1.53) (Fig. 3, Table 3). Here, CCND1 is linked to cancer.